Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer

@article{Stege1988SingleDP,
  title={Single Drug Polyestradiol Phosphate Therapy in Pro static Cancer},
  author={R. Stege and K. Carlstr{\"o}m and L. Collste and A. Eriksson and P. Henriksson and A. Pousette},
  journal={American Journal of Clinical Oncology},
  year={1988},
  volume={11},
  pages={S101–103}
}
  • R. Stege, K. Carlström, +3 authors A. Pousette
  • Published 1988
  • Medicine
  • American Journal of Clinical Oncology
    • Serum concentrations of testosterone (T) and estradiol-17β (E2) were analyzed in prostatic cancer patients treated with 160, 240, or 320 mg polyestradiol phosphate (PEP) i.m. every fourth week as single drug therapy during a 6 month period. Estrogen effects on the liver were studied by analyzing serum levels of sex hormone binding globulin (SHBG) in the 320 mg group and compared with values obtained in patients treated with 80 mg PEP i.m. every fourth week + oral ethinylestradiol (EE2) 150 μg… CONTINUE READING
    View on Wolters Kluwer
    ncbi.nlm.nih.gov
    26 Citations
    Background Citations
    4
    26 Citations
    Citation Type

    Citation Type

    Single‐drug parenteral estrogen treatment in prostatic cancer: A study of two maintenance‐dose regimens
    • 22
    Hormonal regulation of serum lipoprotein (a) levels: effects of parenteral administration of estrogen or testosterone in males.
    • 64
    • PDF
    Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
    • 43
    A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy
    • 22
    IMMEDIATE ESTROGEN OR ESTRAMUSTINE PHOSPHATE THERAPY VERSUS DEFERRED ENDOCRINE TREATMENT IN NONMETASTATIC PROSTATE CANCER: A RANDOMIZED MULTICENTER STUDY WITH 15 YEARS OF FOLLOWUP ROLF LUNDGREN, OMAN NORDLE, KENNETH JOSEFSSON AND THE SOUTH SWEDEN PROSTATE CANCER STUDY GROUP*
    • 3
    Therapy Insight: parenteral estrogen treatment for prostate cancer—a new dawn for an old therapy
    • 32
    Sex hormone--binding globulin--a surrogate marker for the prothrombotic effects of combined oral contraceptives.
    • 22
    Primary orchiectomy versus estrogen therapy in advanced prostatic cancer--a randomized study: results after 7 to 10 years of followup.
    • 28
    Parenteral polyoestradiol phosphate vs orchidectomy in the treatment of advanced prostatic cancer. Efficacy and cardiovascular complications: a 2-year follow-up report of a national, prospective prostatic cancer study. Finnprostate Group.
    • 33
    Prospective evaluation of hot flashes during treatment with parenteral estrogen or complete androgen ablation for metastatic carcinoma of the prostate.
    • 65